aln-5288
Nucleic acidexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2025 (NCT07214727)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Microtubule-associated protein tauANTISENSE INHIBITOR
MAPT antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07214727 | Phase 1 | Oct 15, 2025 | Alnylam Pharmaceuticals, Regeneron |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 1 | 1 | 1 | 2025 |
| Regeneron | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1